相似文献
1
Molecular mediators of angiogenesis.
J Burn Care Res. 2010 Jan-Feb;31(1):158-75. doi: 10.1097/BCR.0b013e3181c7ed82.
2
Molecular control of capillary growth in skeletal muscle.
Can J Appl Physiol. 2002 Oct;27(5):491-515. doi: 10.1139/h02-027.
3
Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61).
Angiogenesis. 2002;5(3):153-65. doi: 10.1023/a:1023823803510.
4
[The role of matrix metalloproteinases and their tissue inhibitors in angiogenesis].
Pol Merkur Lekarski. 2006 Jul;21(121):80-5.
5
Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression.
Curr Opin Hematol. 2008 May;15(3):197-203. doi: 10.1097/MOH.0b013e3282fcc321.
6
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Mol Neurobiol. 2020 May;57(5):2461-2478. doi: 10.1007/s12035-020-01892-8. Epub 2020 Mar 9.
7
Regulation of vascular permeability by vascular endothelial growth factors.
Vascul Pharmacol. 2002 Nov;39(4-5):225-37. doi: 10.1016/s1537-1891(03)00011-9.
8
Matrix metalloproteinases and matrikines in angiogenesis.
Crit Rev Oncol Hematol. 2004 Mar;49(3):203-20. doi: 10.1016/j.critrevonc.2003.10.004.
9
Extracellular Matrix Regulation of Vascular Morphogenesis, Maturation, and Stabilization.
Cold Spring Harb Perspect Med. 2023 Apr 3;13(4):a041156. doi: 10.1101/cshperspect.a041156.
10
[Formation of the vascular bed: a review of its molecular mechanisms and therapeutic implications].
Cas Lek Cesk. 2009;148(4):158-63.
引用本文的文献
1
Coptisine alleviates high glucose-induced HUVEC dysfunction in vitro and inhibits gestational diabetes mellitus in vivo.
J Mol Histol. 2025 Aug 9;56(4):263. doi: 10.1007/s10735-025-10542-z.
2
Bioprinting vascularized skin analogs: a stepwise approach.
Burns Trauma. 2025 Mar 2;13:tkaf018. doi: 10.1093/burnst/tkaf018. eCollection 2025.
3
Inhibition of retinal neovascularization by Dendrobium polysaccharides: a review.
Front Pharmacol. 2025 Jun 30;16:1584553. doi: 10.3389/fphar.2025.1584553. eCollection 2025.
4
Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor.
Biomacromolecules. 2025 Jun 9;26(6):3463-3480. doi: 10.1021/acs.biomac.5c00097. Epub 2025 May 9.
5
Application and Mechanism of Adipose Tissue-Derived Microvascular Fragments in Tissue Repair and Regeneration.
Biomolecules. 2025 Mar 17;15(3):422. doi: 10.3390/biom15030422.
6
Customized Heparinized Alginate and Collagen Hydrogels for Tunable, Local Delivery of Angiogenic Proteins.
ACS Biomater Sci Eng. 2025 Mar 10;11(3):1612-1628. doi: 10.1021/acsbiomaterials.4c01823. Epub 2025 Feb 13.
7
Inhibition of Endothelial Cell Tube Formation by Anti-Vascular Endothelial Growth Factor/Anti-Angiopoietin-2 RNA Nanoparticles.
Pharmaceutics. 2025 Jan 3;17(1):55. doi: 10.3390/pharmaceutics17010055.
8
Exploring the Molecular Modalities in the Pathogenesis of Diabetic Kidney Disease with a Focus on the Potential Therapeutic Implications.
Biomedicines. 2024 Dec 28;13(1):50. doi: 10.3390/biomedicines13010050.
9
Leveraging the predictive power of a 3D in vitro vascularization screening assay for hydrogel-based tissue-engineered periosteum allograft healing.
Biomater Adv. 2025 Apr;169:214187. doi: 10.1016/j.bioadv.2025.214187. Epub 2025 Jan 15.
10
Vascular and Perivascular Role in the Regulation of Angiogenesis: Impact on Arteriovenous Fistula Maturation.
Arch Intern Med Res. 2024;7(4):284-296. doi: 10.26502/aimr.0185. Epub 2024 Nov 27.
本文引用的文献
1
Showing up isn't enough for vascularization: persistence is essential.
Circ Res. 2008 Nov 21;103(11):1200-1. doi: 10.1161/CIRCRESAHA.108.189076.
2
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
J Clin Oncol. 2008 Dec 1;26(34):5583-8. doi: 10.1200/JCO.2008.17.4706. Epub 2008 Nov 3.
3
Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.
Circ Res. 2008 Nov 7;103(10):1092-9. doi: 10.1161/CIRCRESAHA.108.182287. Epub 2008 Oct 2.
4
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Curr Clin Pharmacol. 2008 May;3(2):132-43. doi: 10.2174/157488408784293705.
5
Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90. doi: 10.1073/pnas.0803194105. Epub 2008 Jul 16.
6
Role of platelet-derived growth factors in physiology and medicine.
Genes Dev. 2008 May 15;22(10):1276-312. doi: 10.1101/gad.1653708.
7
Endothelial cell-matrix interactions in neovascularization.
Tissue Eng Part B Rev. 2008 Mar;14(1):19-32. doi: 10.1089/teb.2007.0115.
8
Fibronectin fibrillogenesis regulates three-dimensional neovessel formation.
Genes Dev. 2008 May 1;22(9):1231-43. doi: 10.1101/gad.1643308.
9
Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression.
Curr Opin Hematol. 2008 May;15(3):197-203. doi: 10.1097/MOH.0b013e3282fcc321.
10
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.
Zotero 插件